GA
WX

Geneva Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Geneva Advisors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,870
Closed -$499K – 721
2015
Q1 		$499K Buy
12,870
+570
+5% +$22K 0.01% 418
2014
Q4 		$414K Buy
+12,300
New +$434K 0.01% 450

Other funds holding WX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Geneva Advisors's WX Position: Q2 2015 in Review

Geneva Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q2 2015, closing a stake of 12,870 shares — an estimated $499K sold.

Geneva Advisors first reported a position in WX in Q4 2014 and held it in 2 quarters. The position peaked at $499K in Q1 2015. 154 funds tracked by Wall St. Rank hold WX as of Q2 2015.

  • Geneva Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q2 2015 after selling out during the quarter.
  • Geneva Advisors sold 12,870 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q2 2015, an estimated $499K.
  • Geneva Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2014 and held it in 2 quarters.
  • Geneva Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $499K in Q1 2015.
  • 154 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q2 2015.

Based on Geneva Advisors's 13F filing for Q2 2015, filed 3 Aug 2015.